Oncology | Patient-derived organoid screen | bladder cancer - HUB Organoids

Proven Impact

Our meticulously designed KRASmut panel was instrumental in developing the first-ever clinical candidate using organoid technology, targeting head & neck cancer

read case stady

Panel features

A comprehensive collection of 25 KRASmut PDOs, sourced from both treatment-naïve and pre-treated patients
Rigorously characterized, with readily available DNA and RNA sequencing data
Diverse models encompassing both primary and metastatic tumors
Representing pivotal KRAS mutants such as G12A, G12D, G12V, G13D and many others
Access to invaluable clinical data, including histology data, tumor classification, and patient treatment data

Advanced screening capabilities

ATP-based cell-viability assay, with GR50 readouts
3D assay format, compatible with both 96- and 384-well plate layouts.
Test up to 10 compounds in triplicate
10-point dose-response curves per drug